Potentiation of anti-CD38-Immunotoxin cytotoxicity

Details Potentiation of anti-CD38-Immunotoxin cytotoxicity Potentiation of anti-CD38-Immunotoxin cytotoxicity

2007-05-29

2007-05-29

Canella, Karen A (Department: 1643)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

C424S183100, C514S725000

Reexamination Certificate

active

09226895

ABSTRACT:
The present invention is directed to the use of agents that induce high levels of cell surface molecules to provide targets for immunotoxins directed against the same cell surface molecules. A specific example is given in which all-trans-retinoic acid (RA) is used to induce high levels of CD38 cell surface antigen expression in several myeloid and lymphoid leukemia cells. CD38 was then used as target for delivering plant toxin (gelonin) to leukemia cells. Treatment of leukemia cells with RA induced high levels of CD38 in those cells that otherwise had low CD38 expression. The RA-induced leukemia cells then became exquisitely sensitive to an immunotoxin constructed from an anti-CD38 monoclonal antibody conjugated to the plant toxin gelonin.

REFERENCES:
Meridith et al, “Phase II Study of Dual 131-I Labeled Monoclonal Anitbody Therapy with Interferon in Patients with Metastatic Colon Cancer”, Clinical Cancer Research, vol. 2, pp. 1811-1818, 1996.
Mehta et al, “Retinoic acid-induced CD38 cell surface protein as a target for immunotoxin therapy: In vitro evaluation.” Proceedings of the American Association for Cancer Research, vol. 38, p. 88, 1997.
Hirota et al, “Suppression of an Epidermal Growth Factor Receptor-hyperproducing Tumor by an Immunotoxin Conjugate of Gelonin and a Monolonal Anti-Epidermal Growth Factor Receptor Anitbody.” Cancer Research, vol. 49, pp. 7106-7109, 1989.
Mehta et al, “Introduction of CD39 by Retinoic Acid in Myeloid Leukemia Cells.” Proceedings of the American Association for Cancer Research, vol. 35, p. 92, 1996.
Flavell et al, “Systemic therapy with 3BIT, a triple combination cocktail of . . . anti CD38-saporin immunotoxin”, Cancer Research, vol. 57, pp. 4824-4829, Nov. 1997.
abstract of Zhao et al (Blood, 1994, vol. 84, No. 10, suppl 1, p. 54A).
Scholm (‘Monoclonal Antibodies They'reMore and Less Than You Think’, In: Molecular Foundations of Oncology, 1993, S. Broder, Ed, pp. 95-134).
Drach (Cancer Research, 1994, vol. 54, pp. 1746-1752).
Goldmacher et al (Blood, 1994, vol. 84, pp. 3017-3025).
O'Connor et al (Blood, vol. 86, pp. 4286-4294).
Jacquelyn A. Hank, et al.Clinical and Immunological Effects of Treatment with Murine Anti-CD3 Monoclonal Antibody along with Interleukin 2 in Patients with Cancer. Clinical Cancer Research, vol. 1, pp. 481-491 (May 1995).

Affiliated with

Also associated with

Rating

Potentiation of anti-CD38-Immunotoxin cytotoxicity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Potentiation of anti-CD38-Immunotoxin cytotoxicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Potentiation of anti-CD38-Immunotoxin cytotoxicity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3810120